T7922

Kresoxim-methyl is a strobilurin fungicide,inhibits conidial germination of V. inaequalis isolates from apple orchards .

RSV L-protein-IN-4 (Compound C) is a noncompetitive inhibitor of the RSV polymerase, exhibiting an IC50 of 0.88 μM and demonstrating potent antiviral activity against RSV strains with an EC50 of 0.25 μM [1].

RSV L-protein-IN-5 (Compound E) serves as a potent inhibitor of the Respiratory Syncytial Virus (RSV), with an EC50 value of 0.1 μM. It targets RSV polymerase with an IC50 of 0.66 μM and impedes RSV mRNA synthesis through the inhibition of transcript guanylation. The compound demonstrates moderate cytotoxicity, with a CC50 of 10.7 μM in HEp-2 cells, and effectively reduces viral titers in mouse models of RSV infection [1].

BMPR2-IN-1 (Compound 8a), is a potent inhibitor of BMPR2, exhibiting an IC50 value of 506 nM and a Kd of 83.5 nM. It is utilized in the study of various diseases including pulmonary arterial hypertension, Alzheimer's disease, and cancer [1].

Ara-SH, a derivative of Cytarabine with a mercaptopropionic acid substitution, serves as the initiator for the self-assembly of a smart, co-loaded Cytarabine and Venetoclax nanoparticle (AV-NP), demonstrating notable synergistic antileukemia effects both in vitro and in vivo [1].

α-Amylase/α-Glucosidase-IN-3 (Compound 17) is a dual inhibitor of α-Amylase and α-Glucosidase, with IC50 values of 0.70 μM and 1.10 μM, respectively, applicable for type-II diabetes mellitus research [1].

AMPK Activator 11 is a nanomolar potent inhibitor of cell proliferation in various colorectal carcinomas (CRCs), acting through the selective activation of AMP-activated protein kinase (AMPK) and enhancement of oxidative phosphorylation (OXPHOS) (mitochondrial metabolism). This compound demonstrates particular efficacy in inhibiting RKO xenograft growth, rendering it useful for anti-tumor and metabolic disease research [1].

SARS-CoV-2-IN-50 (Compound X77C) is a potent inhibitor of the SARS-CoV-2 main protease (M^pro), demonstrating high affinity for the enzyme's catalytic site [1].

ETAP, a dual inhibitor of both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), exhibits antidepressant-like effects and is utilized in the research of major depressive disorder [1].